Cullinan Oncology Inc. (CGEM): Price and Financial Metrics
CGEM Price/Volume Stats
| Current price | $7.76 | 52-week high | $21.01 |
| Prev. close | $7.75 | 52-week low | $6.85 |
| Day low | $7.63 | Volume | 1,444,800 |
| Day high | $7.98 | Avg. volume | 450,300 |
| 50-day MA | $8.14 | Dividend yield | N/A |
| 200-day MA | $11.24 | Market Cap | 457.96M |
CGEM Stock Price Chart Interactive Chart >
Cullinan Oncology Inc. (CGEM) Company Bio
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Price Returns
| 1-mo | -10.24% |
| 3-mo | 2.51% |
| 6-mo | -36.29% |
| 1-year | -55.50% |
| 3-year | -39.47% |
| 5-year | N/A |
| YTD | -36.29% |
| 2024 | 19.53% |
| 2023 | -3.41% |
| 2022 | -31.63% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...